drugset / Trial / NCT03556098
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
RandomizedCrossoverDouble-blindBasic science
Summary
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in patients with T1D.
Timeline
- Start
- 2019-02-22
- Primary completion
- 2020-02-11
- Completion
- 2020-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glucose-Dependent Insulin-Releasing Hormone[3-30] | Unknown | — | — |
| Comparator | glucose-dependent insulinotropic peptide | Peptide | — | — |